

F2 54. (Amended) An isolated polynucleotide encoding a breast-tissue specific protein, comprising:

an amino acid sequence selected from the group consisting of SEQ ID NO:31 and ^{the} complement of SEQ ID NO:31. G

F3 57. (Amended) An isolated ^{polynucleotide} ~~gene~~ comprising:
DNA having a sequence selected from the group consisting of SEQ ID NOS:15-16, and ^{the} complements of SEQ ID NOS:15-16. G

REMARKS

Reconsideration of the claimed invention in view of the foregoing amendments and following arguments is respectfully requested. Claims 50, 54, and 57 have been amended. No new matter has been added as a result of these amendments.

SEQUENCE LISTING

Pursuant to the Examiner's request, enclosed is a new Sequence Listing in hard copy and computer readable form.

OBJECTION TO THE SPECIFICATION

The specification is objected to having failing to provide a proper antecedent basis for: "complete compliments" and "degenerate coding sequences thereof". Applicants submit that in view of the amendments to the claims that this rejection is now moot and should be withdrawn.

REJECTION OF CLAIMS 50-53 UNDER 35 U.S.C. §112, FIRST PARAGRAPH

Claims 50-53 are rejected under 35 U.S.C. § 112, first paragraph as containing language not supported in the specification and hence constituting new matter. Claim 50 has been amended. Claims 52-53 are dependent upon Claim 50. In view of the amendment to claim 50, Applicants submit that this rejection should be withdrawn.

109

X

AUG 05 2002

ORIGINAL FILED

REJECTION OF CLAIMS 50-54 UNDER 35 U.S.C. §112, SECOND PARAGRAPH

Claims 50-54 are rejected under 35 U.S.C. under §112, second paragraph as being indefinite. Claims 50 and 54 have been amended. Claims 52-53 are dependent upon Claim 50. In view of the amendments to claims 50 and 54, Applicants submit that this rejection should be withdrawn.

CONCLUSION

In view of the aforementioned amendments and remarks, the aforementioned application is in condition for allowance and Applicant requests that the Examiner withdraw all outstanding objections and rejections and to pass this application to allowance.



23492


ABBOTT LABORATORIES
Telephone: (847) 935-7550
Facsimile: (847) 938-2623

Wood Phillips, Katz, Mortimer & Clark
500 West Madison Street
Suite 3800
Chicago, IL 60662-2511
Phone: (312) 876-2109
Fax: (312) 876-2020

Respectfully submitted,
Patricia A. Billing-Medel, et al.

Mimi C. Goller
Registration No. 39,046
Attorney for Applicants

Respectfully submitted,
Patricia A. Billing-Medel, et al.



Lisa V. Mueller
Registration No. 38,978
Attorney for Applicants

TECH CENTER 1600/2900

AUG 09 2002

RECEIVED

X



MARKED UP VERSION SHOWING CHANGES MADE

50. (Amended) A purified polynucleotide having a sequence selected from the group consisting of SEQ ID NOS:1-3, [complete] complements of SEQ ID NOS:1-3, SEQ ID NO:9, a [complete] complement of SEQ ID NO:9, SEQ ID NOS:14-16, and [complete] complements of SEQ ID NOS:14-16 [and degenerate coding sequences thereof].

54. (Amended) An isolated polynucleotide encoding a breast-tissue specific protein,[the isolated polynucleotide] comprising:
an amino acid sequence selected from the group consisting of SEQ ID NO:31 and a [complete] complement of SEQ ID NO:31.

57. (Amended) An isolated gene comprising:
DNA having a sequence selected from the group consisting of SEQ ID NOS:15-16, and [complete] complements of SEQ ID NOS:15-16 [and degenerate coding sequences thereof].

COPY OF PAPERS
ORIGINALLY FILED

RECEIVED

AUG 08 2002

TECH CENTER

[Handwritten signature]